Ceftazidime for respiratory infections

Bibliography

• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Yost RL, Ramphal R. Ceftazidime review. Drug Intell Clin Pharm 1985;19:509-13
   PubMedGoogle Scholar
• Rains CP, Bryson HM, Peters DH. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995;49:577-617
   PubMed Web of Science ®Google Scholar
• Neu HC. Relation of structural properties of beta-lactam antibiotics to antibacterial activity. Am J Med 1985;79:2-13
   Web of Science ®Google Scholar
• Hayes MV, Orr DC. Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother 1983;12:119-26
   PubMed Web of Science ®Google Scholar
• Jones RN, Jenkins SG, Hoban DJ, In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997 – 1998. Diagn Microbiol Infect Dis 2000;37:93-8
   PubMed Web of Science ®Google Scholar
• Fluit AC, Jones ME, Schmitz FJ, Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000;30:454-60
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone. Antimicrob Agents Chemother 1994;38:2905-7
   PubMedGoogle Scholar
• Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994;38:898-900
   PubMed Web of Science ®Google Scholar
• Gomez-Lus R, Navarro C, Egido P, In vitro activity of cefepime and cefotaxime compared to six other agents against 350 penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Chemother 2000;12:17-21
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1998;30:45-52
   PubMedGoogle Scholar
• Bonfitto P, Lamorgese V, De Vietro T, A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia. J Chemother 1999;11:273-7
   PubMed Web of Science ®Google Scholar
• Ho A, Leung R, Lai CK, Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. Respiration 1997;64:224-8
   PubMedGoogle Scholar
• Leophonte P, Bertrand A, Nouvet G, A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 1993;32(Suppl B):165-73
   PubMedGoogle Scholar
• Rossolini GM, Dryden MS, Kozlov RS, Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 2011;66:151-9
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Jones RN. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005 – 2009). Diagn Microbiol Infect Dis 2011;69:223-7
   PubMed Web of Science ®Google Scholar
• Pillar CM, Torres MK, Brown NP, In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008;52:4388-99
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005 – 2006). Diagn Microbiol Infect Dis 2008;61:86-95
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52:203-8
   PubMed Web of Science ®Google Scholar
• Chung DR, Song JH, Kim SH, High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011;184:1409-17
   PubMed Web of Science ®Google Scholar
• Walkty A, DeCorby M, Lagace-Wiens PR, In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 2011;55:2992-4
   PubMed Web of Science ®Google Scholar
• Jones RN, Stilwell MG, Rhomberg PR, Sader HS. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn Microbiol Infect Dis 2009;65:331-4
   PubMed Web of Science ®Google Scholar
• Chow JW, Fine MJ, Shlaes DM, Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee JE, Park SJ, Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008;52:995-1000
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010;54:969-76
   PubMed Web of Science ®Google Scholar
• Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007;57:341-4
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von Gottberg A, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12
   PubMed Web of Science ®Google Scholar
• Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother 1996;37:203-4
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Hindler J, Loeloff M, Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-46
   PubMed Web of Science ®Google Scholar
• Pai H, Hong JY, Byeon JH, High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2004;48:3159-61
   PubMed Web of Science ®Google Scholar
• Rice LB. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 2012;87:198-208
   PubMed Web of Science ®Google Scholar
• Chantratita N, Rholl DA, Sim B, Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci USA 2011;108:17165-70
   PubMed Web of Science ®Google Scholar
• Richards DM, Brogden RN. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985;29:105-61
   PubMed Web of Science ®Google Scholar
• Roberts JA, Webb SA, Lipman J. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. Int J Antimicrob Agents 2007;29:117-28
   PubMed Web of Science ®Google Scholar
• Bodey GP, Fainstein V, Garcia I, Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis 1983;148:892-7
   PubMedGoogle Scholar
• Armstrong GC, Wise R, Brown RM, Hancox J. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob Agents Chemother 1981;20:356-8
   PubMed Web of Science ®Google Scholar
• Paradis D, Vallee F, Allard S, Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992;36:2085-92
   PubMed Web of Science ®Google Scholar
• Kemmerich B, Warns H, Lode H, Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother 1983;24:333-8
   PubMedGoogle Scholar
• Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999;43:1798-802
   PubMed Web of Science ®Google Scholar
• Hanes SD, Wood GC, Herring V, Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000;179:436-40
   PubMed Web of Science ®Google Scholar
• Perea EJ, Ayarra J, Garcia Iglesias MC, Penetration of cefuroxime and ceftazidime into human lungs. Chemotherapy 1988;34:1-7
   PubMedGoogle Scholar
• Boselli E, Breilh D, Rimmele T, Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004;30:989-91
   PubMed Web of Science ®Google Scholar
• Yangco BG, Palumbo JA, Nolen T, Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia. J Antimicrob Chemother 1986;18:521-9
   PubMedGoogle Scholar
• Vetter N, Feist H, Armbruster C, Drlicek M. Comparison of the effectiveness of ceftazidime and cefazolin/tobramycin in patients with inflammatory diseases of the lower respiratory tract. Infection 1987;15(Suppl 4):S192-4
   PubMedGoogle Scholar
• Huston MJ, Lentino JR. Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infections. Clin Ther 1992;14:595-602
   PubMedGoogle Scholar
• Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001;27:493-502
   PubMed Web of Science ®Google Scholar
• Wolff M. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group. Antimicrob Agents Chemother 1998;42:28-36
   PubMedGoogle Scholar
• Brun-Buisson C, Sollet JP, Schweich H, Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998;26:346-54
   PubMed Web of Science ®Google Scholar
• Bassetti D, Cruciani M, Solbiati M, Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy 1991;37:371-5
   PubMedGoogle Scholar
• Ambrose PG, Richerson MA, Stanton M-E, Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infect Dis Clin Pract 1999;8:245-51
   Web of Science ®Google Scholar
• Alvarez Lerma F. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001;13:70-81
   PubMedGoogle Scholar
• Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997;25:1663-70
   PubMed Web of Science ®Google Scholar
• Joshi M, Bernstein J, Solomkin J, Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 1999;43:389-97
   PubMed Web of Science ®Google Scholar
• Hartenauer U, Weilemann LS, Bodmann KF, Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect 1990;15(Suppl A):61-4
   PubMedGoogle Scholar
• Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993;31:927-37
   PubMed Web of Science ®Google Scholar
• Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995;28:143-60
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Sermaides GJ, Michalopoulos A, Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:581-9
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paratz J, Paratz E, Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:11-18
   PubMed Web of Science ®Google Scholar
• Roberts JA, Boots R, Rickard CM, Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-91
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63
   PubMed Web of Science ®Google Scholar
• MacGowan A. Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol 2011;11:470-6
   PubMed Web of Science ®Google Scholar
• McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21:549-55
   PubMed Web of Science ®Google Scholar
• McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008;31:345-51
   PubMed Web of Science ®Google Scholar
• Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001;45:2643-7
   PubMed Web of Science ®Google Scholar
• Viaene E, Chanteux H, Servais H, Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002;46:2327-32
   PubMed Web of Science ®Google Scholar
• Xu QA, Trissel LA, Saenz CA, Stability of three cephalosporin antibiotics in AutoDose Infusion System bags. J Am Pharm Assoc (Wash) 2002;42:428-31
   PubMedGoogle Scholar
• Das Gupta V, Bethea C, dela Torre M. Chemical stabilities of cefoperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1988;13:199-205
   PubMedGoogle Scholar
• Lu Q, Yang J, Liu Z, Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184:106-15
   PubMed Web of Science ®Google Scholar
• Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995;79:705-19
   PubMed Web of Science ®Google Scholar
• Mouton JW, Brown DF, Apfalter P, The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012;18:E37-45
   PubMed Web of Science ®Google Scholar
• Mouton JW, Dudley MN, Cars O, Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-7
   PubMed Web of Science ®Google Scholar
• Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther 2009;31:2765-78
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, De Waele JJ, What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012;39:455-7
   PubMed Web of Science ®Google Scholar
• Lipman J, Udy AA, Roberts JA. Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011;39:999-1000
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M, NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008;62:1053-6
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Claudon M, In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012;56:1606-8
   PubMed Web of Science ®Google Scholar
• Curcio D. Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. Expert Rev Anti Infect Ther 2011;9:173-6
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens PR, Tailor F, Simner P, Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 2011;55:2434-7
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4
   PubMed Web of Science ®Google Scholar
• Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39:86-9
   PubMed Web of Science ®Google Scholar
• Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978;24:45-54
   PubMed Web of Science ®Google Scholar
• Carratala J, Mykietiuk A, Fernandez-Sabe N, Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1393-9
   PubMed Web of Science ®Google Scholar
• Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328:668
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4:519-27
   PubMed Web of Science ®Google Scholar
• Yu VL. Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis 2011;11:248-52
   PubMed Web of Science ®Google Scholar
• Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010;10:279-87
   PubMed Web of Science ®Google Scholar
• Kett DH, Cano E, Quartin AA, Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011;11:181-9
   PubMed Web of Science ®Google Scholar